Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06195670
Other study ID # HMPL-013-FLAG-C124
Secondary ID
Status Not yet recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date January 2024
Est. completion date January 2027

Study information

Verified date December 2023
Source Zhejiang Cancer Hospital
Contact Ji Zhu, M.D.
Phone 0571-88128142 ext +86
Email leozhu@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to evaluate the efficacy and safety of short course radiotherapy followed by fruquintinib combined with Sintilimab as the first-line treatment of advanced mCRC compared to bevacizumab combined with capecitabine in patients unfit for intensive therapy.


Description:

Anti-angiogenic therapy combined with immune checkpoint inhibitors in advanced mCRC has shown promising efficacy with acceptable toxicities. Radiotherapy may reshape the tumor immune microenvironment, thereby improving the efficacy of subsequent anti angiogenic drugs combined with immunotherapy. The study is a prospective, multi-centered, two-stage clinical study with 220 unresectable advanced mCRC patients unfit for oxaliplatin or irinotecan-based intensive chemotherapy enrolled. In phase 1b, 20 patients will be recruited and the efficacy and safety of SCRT followed by fruquintinib plus sintilimab will be explored. In phase 2, 200 patients will be randomized and the efficacy and safety will be compared between SCRT followed by fruquintinib plus sintilimab and capecitabine plus bevacizumab.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 220
Est. completion date January 2027
Est. primary completion date January 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - Have signed an informed consent; - 18 to 85 years old (including 18 and 85 years old); - Histopathologically confirmed unresectable advanced metastatic colorectal adenocarcinoma; - Have not received anti-tumor treatment for metastatic disease; - Inability to tolerate intensive treatment regimens based on oxaliplatin or irinotecan as determined by researchers; - At least one measurable lesion; - Expected life expectancy = 12 weeks; - The function of important organs within the 14 days prior to enrollment meets the following requirements (no blood components or cell growth factors are allowed to be used within the 14 days prior to enrollment): - Neutrophil absolute count = 1.5 × 10^9/L; - Platelets = 80 × 10^9/L; - Hemoglobin = 8g/dL; - Total bilirubin<1.5 times ULN; - ALT and AST<2.5 times ULN (liver metastasis patients<5 times ULN); - Serum creatinine = 1.5 times ULN; - Endogenous creatinine clearance rate>50ml/min; - International standardized ratio (INR) of coagulation function = 1.5 × ULN, prothrombin time (PT) and activated partial thromboplastin time (APTT) = 1.5 × ULN - Women of childbearing age or men whose partners have a desire to conceive should take effective contraceptive measures. Exclusion Criteria: - Currently has a disease or condition that affects drug absorption, or the patient is unable to take oral drugs; - Currently has digestive tract diseases such as active gastric and duodenal ulcers, ulcerative colitis, or active bleeding from unresectable tumors, or other conditions determined by the researcher that may cause gastrointestinal bleeding or perforation; - History of serious cardiovascular and cerebrovascular diseases; - Other malignant tumors within the past 5 years, excluding skin basal cell or squamous cell carcinoma after radical surgery, or cervical carcinoma in situ; - Clinically uncontrolled active infection, such as acute pneumonia, active hepatitis B or hepatitis C (hepatitis B virus DNA = 1 × 104 copies/mL or>2000 IU/ml); - Currently has central nervous system (CNS) metastasis or has a history of unstable or clinically symptomatic brain metastasis; - Pregnant (positive pregnancy test before medication) or breastfeeding women; - Urine protein = 2+, or 24-hour urine protein >1.0g; - Histologically confirmed MSI-H/dMMR tumors; - Patients deemed unsuitable by the researchers for inclusion in this study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Experimental
SCRT: 5*5Gy for 5 days, after a one-week rest, with fruquintinib plus sintilimab followed; Fruquintinib: qd po, 4mg/d, 2weeks on/1 week off, q3w; Sintilimab: intravenous infusion, 200mg, on day 1, q3w.
Active Comparator
Capecitabine: bid po, 1000mg/m², on days 1-14, q3w; Bevacizumab: intravenous infusion, 7.5mg/kg, on day 1, q3w.

Locations

Country Name City State
China Ji Zhu Hangzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
Zhejiang Cancer Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Phase 1b - Objective Response Rate (ORR) ORR according to RECIST v1.1, as assessed by the Investigator From randomization until disease progression (up to approximately 3-5 years)
Primary Phase 2 - Progression-free Survival (PFS) PFS according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, as assessed by the Investigator From randomization until disease progression (up to approximately 3-5 years)
Secondary Tolerability and safety of study regimens Number of Participants With Treatment-emergent Adverse Events (TEAEs) according to CTCAE v5.0 From randomization until the end of treatment (up to approximately 3-5 years)
Secondary Disease Control Rate (DCR) DCR according to RECIST v1.1, as assessed by the Investigator From randomization until disease progression (up to approximately 3-5 years)
Secondary Overall Survival OS) OS according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, as assessed by the Investigator From randomization until disease progression (up to approximately 3-5 years)
See also
  Status Clinical Trial Phase
Completed NCT01228734 - A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients Phase 3
Completed NCT05178745 - A Prospective Observational Cohort Study Evaluating Resection Rate in Patients With Metastatic Colorectal Cancer Treated With Aflibercept in Combination With FOLFIRI - Observatoire résection
Completed NCT01591421 - P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer. Phase 1/Phase 2
Withdrawn NCT05412706 - Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction Therapy Phase 2
Withdrawn NCT04430985 - FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer Phase 2
Withdrawn NCT03182894 - Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer Phase 1/Phase 2
Recruiting NCT05725200 - Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer Phase 2
Terminated NCT03176264 - PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer Phase 1
Completed NCT04866290 - HepaSphere™ Microspheres Prospective Registry
Not yet recruiting NCT06425133 - Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers Phase 2
Not yet recruiting NCT05531045 - 18FFDG PET/CT for Early Evaluation of Chemotherapy Efficacy in Metastatic Colic Adenocarcinoma
Withdrawn NCT03982173 - Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors Phase 2
Completed NCT02906059 - Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer Phase 1
Active, not recruiting NCT02575378 - Maintenance Treatment With Capecitabine Metronomic Chemotherapy and Chinese Traditional Medicine in Metastatic Colorectal Cancer Phase 4
Withdrawn NCT02535988 - Abscopal Effect for Metastatic Colorectal Cancer Phase 2
Recruiting NCT02848807 - Chemotherapy-related Toxicity, Nutritional Status and Quality of Life N/A
Active, not recruiting NCT02077868 - Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment Phase 3
Completed NCT02414009 - Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients Phase 2
Active, not recruiting NCT01949194 - Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers Phase 2
Withdrawn NCT01915472 - A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer Phase 2